#United States #New York #Class Action #Applied Therapeutics #Wolf Popper

Overview of the Settlement

Recently, Wolf Popper LLP announced an important legal development regarding a class action settlement for investors who purchased common stock from Applied Therapeutics, Inc. (ATNX). The securities litigation, filed in the United States District Court for the Southern District of New York, concerns transactions occurring between January 3, 2024, and December 2, 2024.

Background of the Case

Applied Therapeutics faced legal challenges as investors alleged that they had suffered losses due to misleading information presented by the company. This prompted a legal class action against Applied Therapeutics, asserting that essential facts were withheld from potential investors which could have influenced their decisions.

Key Details:

• - Class Definition: Those who purchased or acquired shares on U.S. exchanges are included in the class.
• - Proposed Settlement Amount: The total is $15 million, plus warrants enabling the purchase of up to 1 million additional shares at a set price.
• - Settlement Hearing Date: March 19, 2026.

Next Steps for Affected Investors

All eligible participants, defined as class members, are encouraged to file a claim to secure benefits from the settlement fund. Failure to do so before the deadline of April 8, 2026, will lead to rejection of claims.

How to File a Claim

1. Access the Claim Form: Download the Proof of Claim and Release form from www.APLTSecuritiesSettlement.com.
2. Submission: Claims can be submitted either electronically via the website or through mail, but must be postmarked no later than April 8, 2026.
3. Exclusion Rights: If you wish to opt out, a formal request must be submitted by February 26, 2026. It is crucial to ensure that your opt-out form is completed correctly to be valid.

Why This Settlement Matters

This settlement serves as a precedent in investor rights, reinforcing the necessity for public companies to maintain transparency regarding financial health and operations. Investors are reminded that their participation in similar future settlements can shape corporate accountability.

Legal Counsel and Further Information

Wolf Popper LLP is leading the legal strategy for these class members. Affected individuals should refrain from contacting the court or the defendants and instead reference their website or claims administrator for specific inquiries.

For further assistance, details on objections to the settlement, and more information, investors can reach out to:

• - Claims Administrator for the Settlement: 1650 Arch Street, Suite 2210, Philadelphia, PA 19103.
• - Wolf Popper Contact: Joshua W. Ruthizer, 845 Third Avenue, 12th Floor, New York, NY 10022, at telephone number 877-370-7703.

Conclusion

The proposed settlement is an assertion of justice for investors affected by the alleged discrepancies related to Applied Therapeutics' operations. Active participation in this settlement may allow affected stakeholders to recover losses, thus encouraging the principle of accountability in the finance sector.